参考文献/References:
[1] American Thyroid Association (ATA) Guidelines Taskfouce on Thyroid Nodules and Differentiated Thyroid Cancer,Cooper DS,Doherty G M,et al.Revised American Thyroid Association manage-ment guidelines for patients with thyroid nodules and differentiated thyroid cancer.Thyroid,2009,19(11):1167-1214.
[2] Kim TY,Kim WB,Kim ES,et al.Serum thyroglobbulin levels at the time of 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with dif-ferentiated thyroid carcinoma.J Clin Endocrinol Metab,2005,90(3):1440-1445.
[3] Heemstra KA,Liu YY,Stokkel M,et al.Serum thyroglobulin con-centrations perdict disease-free remission and death in differentiat-ed thyroid carcinoma.Clin Endocrinol(Oxf),2007,66(1):58-64.
[4] Suh I,Vrients MR,Guerrero MA,et al.Serum thyroglobulin is a poor diagnostic biomarker of malignancy in follicular and Hurthle-cell neoplasms of the thyroid.Am J Surg,2010,200(1):41-46.
[5] 高再荣,常伟,崔坤炜,等.甲状腺乳头状癌术后刺激状态Tg预测131I清甲治疗后Tg水平的价值.中华核医学杂志,2009,29(3):156-159.
[6] 李田军,林岩松,梁军,等.131I治疗前刺激性Tg对乳头状甲状腺癌远处转移的预测价值.中华核医学与分子影像杂志,2012,32(3):189-191.
[7] Lundgren CI,Hall P,Dickman PW,et al.Clinically significant prognostic factors for differentiated thyoid carcinoma:a population-based,nested case-control study.Cancer,2006,106(3):524-531.
[8] Bilimoria KY,Bentrem DJ,Ko CY,et al.Extent of surgery affects survival for papillary thyroid cancer.Ann Surg,2007,246(3):375-384.
[9] Sawka AM,Orlov S,Gelberg J,et al.Prognostic value of postsurgi-cal stimulated thyroglobulin levels after initial radioactive iodine therapy in well-differentiated thyroid carcinoma.Head Neck,2008,30(6):693-700.
[10] Low TH,Delbridge L,Sidhu S,et al.Lymph node status influences follow-up thyroglobulin levels in papillary thyroid cancer.Ann Surg Oncol,2008,15(10):2827-2832.
相似文献/References:
[1]李景涛,邓垒,张文珏,等.广泛期小细胞肺癌胸部IMRT后发生放射性肺炎的危险因素分析[J].国际放射医学核医学杂志,2016,40(2):100.[doi:10.3760/cma.j.issn.1673-4114.2016.02.003]
Li Jingtao,Deng Lei,Zhang Wenjue,et al.Risk factor analysis for predicting radiation pneumonitis in extensive stage small cell lung cancer patients receiving IMRT thoracic radiotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):100.[doi:10.3760/cma.j.issn.1673-4114.2016.02.003]
[2]李盼丽,宋少莉.碘难治性分化型甲状腺癌靶向药物治疗进展[J].国际放射医学核医学杂志,2016,40(3):202.[doi:10.3760/cma.j.issn.1673-4114.2016.03.009]
Li Panli,Song Shaoli.Radioactive iodine refractory differentiated thyroid cancer targeted therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):202.[doi:10.3760/cma.j.issn.1673-4114.2016.03.009]
[3]杨珂,唐波,于夕荣,等.甲状腺癌131i治疗病房的辐射屏蔽计算与评价[J].国际放射医学核医学杂志,2015,39(5):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
yang ke,tang bo,yu xirong,et al.shielding calculation and assessment in 131i therapy for thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
[4]张毓艺,姚稚明.18F-FDG PET/CT对非小细胞肺癌淋巴结分期诊断价值的研究进展[J].国际放射医学核医学杂志,2016,40(6):447.[doi:10.3760/cma.j.issn.1673-4114.2016.06.009]
Zhang Yuyi,Yao Zhiming.The progress of 18F-FDG PET/CT in the diagnosis of N-staging of non-small cell lung cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):447.[doi:10.3760/cma.j.issn.1673-4114.2016.06.009]
[5]陈立,陈跃.分化型甲状腺癌骨转移诊断及疗效评价的核素显像研究进展[J].国际放射医学核医学杂志,2016,40(6):452.[doi:10.3760/cma.j.issn.1673-4114.2016.06.010]
Chen Li,Chen Yue.Diagnosis and evaluation of curative effect progress of radionuclide imaging methods in differentiated thyroid cancer of bone metastases[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):452.[doi:10.3760/cma.j.issn.1673-4114.2016.06.010]
[6]惠金子,赵德善.Tg、TgAb及TSH在分化型甲状腺癌术前的预测分析[J].国际放射医学核医学杂志,2015,39(2):110.[doi:10.3760/cma.j.issn.1673-4114.2015.02.002]
Hui Jinzi,Zhao Deshan.The prediction of risk of differentiated thyroid carcinoma with preoperative serum thyroid stimulating hormone, thyrogiobulin and antithyroglobulin antibody[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):110.[doi:10.3760/cma.j.issn.1673-4114.2015.02.002]
[7]万绪明,许祖闪,侯红军.磁共振表观弥散系数变化率对肝细胞肝癌患者单次TACE术后疗效评价的应用价值[J].国际放射医学核医学杂志,2015,39(2):129.[doi:10.3760/cma.j.issn.1673-4114.2015.02.006]
Wan Xuming,Xu Zushan,Hou Hongjun.Applieation value of the change ratio of apparent diffusion coefficient in the therapeutic evaluation of hepatocellular carcinoma treated by single transcatheter arterial chemoembolization[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):129.[doi:10.3760/cma.j.issn.1673-4114.2015.02.006]
[8]刘斌,潘明志.BRAF基因突变对甲状腺乳头状癌诊治价值的研究进展[J].国际放射医学核医学杂志,2015,39(2):154.[doi:10.3760/cma.j.issn.1673-4114.2015.02.011]
Liu Bin,Pan Mingzhi.Advances in value of BRAF gene mutation on the diagnosis and treatment of papillary thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):154.[doi:10.3760/cma.j.issn.1673-4114.2015.02.011]
[9]王振光,王洋洋.PET/CT显像在肝细胞肝癌诊断中的研究进展[J].国际放射医学核医学杂志,2015,39(2):175.[doi:10.3760/cma.j.issn.1673-4114.2015.02.016]
Wang Zhenguang,Wang Yangyang.The development of PET/CT imaging in the diagnosis of hepatocellular carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):175.[doi:10.3760/cma.j.issn.1673-4114.2015.02.016]
[10]胡斌,王锦锋,毛秋粉.18F-FDG PET/CT显像在Tg阳性131I全身显像阴性的分化型甲状腺癌患者中的应用价值[J].国际放射医学核医学杂志,2015,39(3):242.[doi:10.3760/cma.j.issn.1673-4114.2015.03.012]
Hu Bin,Wang Jinfeng,Mao Qiufen.The application value of 18F-FDG PET/CT in patients with differentiated thyroid cancer of high thyroglobulin level and negative 131I whole body scan[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):242.[doi:10.3760/cma.j.issn.1673-4114.2015.03.012]